MYD88 and diffuse large B-cell lymphoma: Meanwhile, the addition of a BTKi may improve the prognosis of non-GCB, DEL or high-IPI-score DLBCL patients with MYD88<sup>mut</sup> and/or CD79B<sup>mut</sup> .